Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) - PubMed
5 hours ago
- #pharmacovigilance
- #cancer risk
- #DPP4 inhibitors
- The study investigates the potential link between DPP4 inhibitors (used for type 2 diabetes) and cancer risk using the FDA Adverse Event Reporting System (FAERS).
- Analysis of FAERS data (2019-2024) identified 3,764 adverse event reports related to malignancies in T2DM patients on DPP4 inhibitors.
- Sitagliptin showed the strongest association with cancer-related adverse events, including malignancies, tumor lysis syndrome, and site-specific neoplasms.
- Patients reporting malignancy-related adverse events were predominantly over 70 years old.
- The median time to adverse event onset for DPP4 inhibitors was 13-15 months in larger studies.
- The findings suggest a need for further large-scale prospective studies to validate these risks and understand underlying mechanisms.